I-Mab: Trading Below Net Cash With Multiple Upside Options

MF3d I-Mab (NASDAQ:IMAB) Biopharma is a clinical-stage biotech company with a focus on immunotherapies and oncology. The company recently announced that it has signed agreement to divest its assets and business operations in China (the Hangzhou Company) to become a U.S-based biotech company. After the divesting, I-Mab will have a healthy balance sheet with more than $400 million in cash, a pipeline consists of three potential best-in-class clinical stage oncology assets, the potential to receive up to $ ...